Сравнение

Carbetocin vs. Pasireotid

Два пептида рядом — идентичность, доказательная база, правовой статус и известные нежелательные явления.

Идентичность

Категория

Исследования (прочее)

Номер CAS

37025-55-1

396091-73-9

Молекулярная масса

нет данных

1047.21 g/mol

Период полувыведения

0.67 h

нет данных

Последовательность

нет данных

Механизм действия

Carbetocin

Carbetocin is an oxytocin receptor agonist with prolonged duration. It triggers a sustained contraction of the uterus after birth, preventing atonic hemorrhage — unlike oxytocin, without a multi-hour infusion.

Pasireotid

Pasireotide binds more broadly than older somatostatin analogs (SSTR1/2/3/5) with particularly high affinity for SSTR5. This suppresses, among others, ACTH release in Cushing's disease and GH release in acromegaly.

Доказательная база

Наивысшая доказательность

РКИ на людях

Исследования

из них на людях

Зафиксированные эффекты

Открытые противоречия

Задокументированные нежелательные явления

Правовой статус

Country	Carbetocin	Pasireotid
Германия	Рецептурный	Рецептурный
США	Не одобрено	Рецептурный

Полные записи

Frequently asked questions

What is the difference between Carbetocin and Pasireotid?: Carbetocin is classified as "Исследования (прочее)", while Pasireotid is classified as "Исследования (прочее)". Carbetocin: Carbetocin is a long-acting synthetic oxytocin analog (half-life ~40 minutes). It prevents postpartum hemorrhage as a single injection. Approved in Canada and the UK among others, NOT in the US. Pasireotid: Pasireotide is a multireceptor somatostatin analog binding to four of the five somatostatin receptors (especially SSTR5). It is approved for Cushing's disease and acromegaly. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Carbetocin or Pasireotid?: The highest available evidence level is "РКИ на людях" for Carbetocin and "РКИ на людях" for Pasireotid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Carbetocin and Pasireotid in Germany and the United States?: Германия: Carbetocin — Рецептурный, Pasireotid — Рецептурный. США: Carbetocin — Не одобрено, Pasireotid — Рецептурный. These are factual summaries with source and review date on the individual pages.

Country

Carbetocin

Pasireotid

Германия

Рецептурный

США

Не одобрено

Рецептурный

Frequently asked questions

What is the difference between Carbetocin and Pasireotid?

Carbetocin is classified as "Исследования (прочее)", while Pasireotid is classified as "Исследования (прочее)". Carbetocin: Carbetocin is a long-acting synthetic oxytocin analog (half-life ~40 minutes). It prevents postpartum hemorrhage as a single injection. Approved in Canada and the UK among others, NOT in the US. Pasireotid: Pasireotide is a multireceptor somatostatin analog binding to four of the five somatostatin receptors (especially SSTR5). It is approved for Cushing's disease and acromegaly. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Carbetocin or Pasireotid?

The highest available evidence level is "РКИ на людях" for Carbetocin and "РКИ на людях" for Pasireotid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Carbetocin and Pasireotid in Germany and the United States?

Германия: Carbetocin — Рецептурный, Pasireotid — Рецептурный. США: Carbetocin — Не одобрено, Pasireotid — Рецептурный. These are factual summaries with source and review date on the individual pages.